AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-18859255_ITM" title="Facts and information about UCB, Biogen Idec to collaborate on oral multiple sclerosis therapy.">UCB, Biogen Idec to collaborate on oral multiple sclerosis therapy.</a>
Close
Set up an RSS feed that alerts you when new articles from Europe Intelligence Wire are available.
Frequently asked questions about RSS feeds
UCB, Biogen Idec to collaborate on oral multiple sclerosis therapy.
(From AFX Europe (Focus))
LONDON (AFX) - Belgium's UCB SA and US-based Biogen Idec said they will collaborate to jointly develop and market CDP323 for the treatment of multiple sclerosis.
CDP323 is a small molecule inhibitor expected to enter Phase II clinical trials next year.
UCB will receive upfront and additional payments for development and commercial milestones in excess of 200 mln usd. Biogen Idec will contribute to …
Related articles from newspapers, magazines, journals, and more
-
- Biogen Idec, Elan release positive phase III data on TYSABRI for MS treatment.
-
News wire article from: Europe Intelligence Wire
September 28, 2006
700+ words
-
- Biogen Idec Q4 earnings double.
-
News wire article from: Europe Intelligence Wire
February 15, 2007
700+ words
-
- Biogen Idec signs deal to develop, commercialise hypertension drug Aviptadil.
-
News wire article from: Europe Intelligence Wire
September 14, 2006
700+ words
-
- Biogen Idec, Elan receive approval from Canadian regulator for TYSABRI MS drug.
-
News wire article from: Europe Intelligence Wire
October 4, 2006
700+ words
-
- AFX economic and business calendar.
-
News wire article from: Europe Intelligence Wire
February 15, 2007
700+ words
